Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verona Pharma PLC VRNA

Healthcare
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual... see more

Recent & Breaking News (NDAQ:VRNA)

Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update

GlobeNewswire July 30, 2019

Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference

GlobeNewswire July 24, 2019

Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine

GlobeNewswire June 25, 2019

Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD

GlobeNewswire June 4, 2019

Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference

GlobeNewswire May 30, 2019

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference

GlobeNewswire May 20, 2019

Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019

GlobeNewswire May 7, 2019

Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials

GlobeNewswire May 7, 2019

Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference

GlobeNewswire May 2, 2019

Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update

GlobeNewswire May 1, 2019

Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker

GlobeNewswire May 1, 2019

Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019

GlobeNewswire April 25, 2019

Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 26, 2019

Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference

GlobeNewswire February 28, 2019

Verona Pharma to Present at Upcoming Investor Conferences

GlobeNewswire February 4, 2019

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

GlobeNewswire January 14, 2019

Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554

GlobeNewswire January 9, 2019

Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554

GlobeNewswire January 3, 2019

Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD

GlobeNewswire December 17, 2018

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018

GlobeNewswire November 6, 2018